Protara Therapeutics reported a second quarter 2026 net loss of $21.7 million, or $0.36 per share, as the company ramped up clinical activity for its lead oncology and rare disease candidates. The company ended the period with a robust liquidity position of $161.9 million, providing a projected cash runway into 2028.
Key Highlights
- The company expects to complete enrollment of the BCG-Unresponsive registrational cohort in the ADVANCED-2 trial by the fourth quarter of 2026.
- Research and development expenses rose to $17.0 million from $10.8 million year-over-year, driven by a $3.2 million increase in direct clinical trial costs.
- Updated interim data for TARA-002 in Lymphatic Malformations showed an 83% clinical success rate in participants who completed treatment.